Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
A

PI3Ki's in Indolent Lymphoma: Overview of Approved Drugs, Trial Based Data on Toxicity and Efficacy of Upcoming PI3Ki's, and the Pre-Clinical Rationale of PI3Ki's+Targeted

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Andrew Zelenetz
By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Andrew Zelenetz
68 views
October 18, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
Lymphoma
16:05
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: What Is High Risk MCL and How Should We Treat It

Feat. A. Kumar
21:58
MedNews Week

The Evolving 1L DLBCL Landscape: POLARIX, Novel Agents and Future Di…

Feat. M. Matasar
24:57
MedNews Week

Current Management of Newly Diagnosed DLBCL

Feat. M. Matasar
18:10
SOHO Brazil 2023

2023 SOHO® Brazil: "Moving Beyond CHOP/CHOEP - How Disease Feat…

Feat. A. Moskowitz
38:55
Indy Hematology Review

Managing Indolent and Mantle Cell Lymphomas With Targeted and Cellul…

Feat. G. Salles
07:46
ASCO 2022 Conference Coverage

ASCO 2022 on the Initial Safety Run-in Results of the Phase III POLA…

Feat. M. Matasar
05:16
ASCO 2022 Conference Coverage

ASCO 2022 Updated Interim Analysis of the Randomized Phase 1b/3 Stud…

Feat. C. Lee Batlevi
34
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Updated Interim Analysis of the Randomiz…

Feat. C. Lee Batlevi
12:32
Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

SOHO 2021: The Next Wave of Novel Agents in Aggressive B-Cell Lympho…

Feat. G. Salles
10:28
i3 Health

MSKCC 2021 Update on Therapeutic Advances in T-Cell Lymphoma: Subtyp…

Feat. S. Horwitz
24:05
SOHO Highlights: State of the Art and Next Questions

SOHO Highlights on Non-Bulky cHL: Can We Treat Early Disease With Sh…

Feat. D. Straus
11:39
SOHO Highlights: State of the Art and Next Questions

Early Stage cHL Management: Bulky vs. Non-bulky Disease, Better Chem…

Feat. D. Straus
15:22
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on R/R PTCL: Is There a Single Paradigm Overall? Ca…

Feat. S. Horwitz
21:36
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on Newly Diagnosed HL: Is ABVD Chemo Regimen Be…

Feat. D. Straus
09:59
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on R/R cHL: Can We Improve Chemo With ADCs and CPI…

Feat. D. Straus
11:13
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on DLBCL: CAR-T vs. autoHCT for Early Relapsed Dise…

Feat. S. Giralt
22:53
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020

2019 ASH Update on the First-Line Therapy in Follicular Lymphoma: Ri…

Feat. A. Zelenetz
22:19
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020

PI3K Inhibitors Are Highly Active in R/R Follicular Lymphoma, New Do…

Feat. A. Zelenetz
07:09
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Next Questions in DLBCL: New Genetic Classification Based Selection …

Feat. A. Younes
15:47
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Who Is a Candidate for Watch and Wait Therapy in MCL / What Are the …

Feat. A. Kumar
15:41
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

PI3Ki's in Indolent Lymphoma: Overview of Approved Drugs, Trial…

Feat. A. Zelenetz
15:30
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Marginal Gastric Zone Lymphoma: The Role of Radiation Therapy

Feat. J. Yahalom
28:25
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Does RCHOP Stay the Standard of Care After 6 Cycles in Advanced/R DL…

Feat. A. Younes
13:26
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

The Role of Venetoclax in DLBCL: Efficacy and Safety Results from th…

Feat. A. Zelenetz
11:13
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Treating Elderly Patients with Hodgkin Lymphoma - How Much Bleomycin…

Feat. A. Moskowitz
23:38
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Ongoing Efforts to Improve the Safety of CAR T-Cell Therapy: Cytokin…

Feat. B. Santomasso
10:01
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Primary CNS Lymphoma - Clinical Features & Staging, Pretreatment…

Feat. C. Grommes
13:27
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Treatment of Primary CNS Lymphoma: Upfront Regimen, Surgery, Treatme…

Feat. C. Grommes
13:57
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Targeted Therapies in CNS Lymphoma & Salvage Options per NCCN Gu…

Feat. C. Grommes